Nazara Technologies completed the allotment of 1.33 crore equity shares after warrant conversions, receiving ₹259.95 crore. The new shares rank equally with existing ones. This capital infusion strengthens the company's financial position, though it leads to equity dilution for existing shareholders.
Nazara Technologies Completes Warrant Conversion, Infuses ₹259.95 Crore
Nazara Technologies has allotted 1,33,31,000 equity shares following the conversion of warrants, bringing in ₹259.95 crore to the company. The newly issued shares will have the same rights as existing ones.
Reader Takeaway: ₹259.95 Cr capital infusion strengthens finances; equity dilution is a key consideration.
What just happened
Nazara Technologies has finalized the allotment of 1,33,31,000 equity shares. This follows the conversion of warrants, for which the company received ₹259.95 crore. The conversion price was 75% of the warrant issue price.
Why this matters
The infusion of ₹259.95 crore bolsters Nazara Technologies' cash reserves. This capital can be used for growth initiatives. The allotment demonstrates investor confidence in the company's future prospects.
The backstory
Nazara Technologies had previously received approval from its Board of Directors to allot these shares. The company had obtained in-principle approvals from stock exchanges BSE and NSE on May 22, 2026. The process aligns with SEBI ICDR Regulations and the Companies Act, 2013.
What changes now
The company's paid-up equity share capital has increased from 37,04,65,024 shares to 38,37,96,024 shares. This signifies a dilution in the ownership percentage for existing shareholders.
Risks to watch
- Equity Dilution: The issuance of new shares will dilute the stake of existing shareholders. Investors need to assess if the deployment of the new capital justifies this dilution.
- Lock-in Period: The newly allotted shares are subject to a lock-in period as per SEBI regulations, which means they cannot be traded immediately.
Peer comparison
While specific peer actions are not detailed in the filing, capital raises via warrant conversion are common in the gaming and technology sectors in India. Companies often use such infusions to fund expansion, acquisitions, or R&D.
Context metrics (time-bound)
The Board of Directors approved the allotment via circulation on July 30, 2026. In-principle approvals from BSE and NSE were received on May 22, 2026.
What to track next
Investors will be keen to observe how Nazara Technologies utilizes the ₹259.95 crore capital infusion to drive future growth and enhance shareholder value.